Influence of the rs738409 polymorphism in patatin‐like phospholipase 3 on the treatment efficacy of non‐alcoholic fatty liver disease with type 2 diabetes mellitus

A genome‐wide association study revealed that the single nucleotide polymorphism (SNP) rs738409 in the patatin‐like phospholipase 3 gene (PNPLA3) was strongly associated with non‐alcoholic fatty liver disease (NAFLD). Recent pilot studies investigated the effects of dipeptidyl peptidase‐4 inhibitors on liver function and glucose metabolism in NAFLD with type 2 diabetes mellitus (DM). We herein evaluated the efficacy of alogliptin in NAFLD patients with type 2 DM as well as the relationship between genotypes at rs738409 in PNPLA3 and treatment efficacy.

[1]  V. Wong,et al.  PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease , 2015, Journal of gastroenterology and hepatology.

[2]  P. Balakumar,et al.  Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. , 2013, Cellular signalling.

[3]  K. Petersen,et al.  Role of Patatin-Like Phospholipase Domain-Containing 3 on Lipid-Induced Hepatic Steatosis and Insulin Resistance in Rats , 2013, Hepatology.

[4]  Y. Yılmaz,et al.  Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. , 2012, Acta gastro-enterologica Belgica.

[5]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[6]  Y. Terauchi,et al.  Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. , 2011, Hepato-gastroenterology.

[7]  K. Parsa,et al.  Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview , 2011, Expert opinion on drug discovery.

[8]  Y. Terauchi,et al.  Protective Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor against Increased β Cell Apoptosis Induced by Dietary Sucrose and Linoleic Acid in Mice with Diabetes* , 2011, The Journal of Biological Chemistry.

[9]  Y. Terauchi,et al.  Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice , 2011, Diabetes.

[10]  T. Okanoue,et al.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan , 2011, Journal of gastroenterology and hepatology.

[11]  A. Sekine,et al.  Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease , 2010, BMC Medical Genetics.

[12]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[13]  J. Féher,et al.  Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker , 2010, PloS one.

[14]  Yusuke Nakamura,et al.  Genome-wide association study of hematological and biochemical traits in a Japanese population , 2010, Nature Genetics.

[15]  Nick V. Grishin,et al.  A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis , 2009, The Journal of Biological Chemistry.

[16]  D. Nathan,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[17]  Z. Goodman,et al.  Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  J. Shaw,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[19]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  T. Karlsen.  Genetic variation in PNPLA 3 confers susceptibility to nonalcoholic fatty liver disease , 2009 .

[21]  Luigi Ferrucci,et al.  Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. , 2008, American journal of human genetics.

[22]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[23]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[24]  C. Day,et al.  Genes and nonalcoholic fatty liver disease , 2008, Current diabetes reports.

[25]  Khean-Lee Goh,et al.  How common is non‐alcoholic fatty liver disease in the Asia–Pacific region and are there local differences? , 2007, Journal of gastroenterology and hepatology.

[26]  M. Taniai,et al.  Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. , 2007, Journal of hepatology.

[27]  P. Angulo,et al.  Obesity and nonalcoholic fatty liver disease. , 2007, Nutrition reviews.

[28]  G. Musso,et al.  Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH? , 2007, Hepatology.

[29]  W. Zeng,et al.  Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans , 2007, Drug Metabolism and Disposition.

[30]  W. Zeng,et al.  Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [ 14 C ] Sitagliptin in Humans , 2007 .

[31]  Roger Williams.  Global challenges in liver disease , 2006, Hepatology.

[32]  T. Omatsu,et al.  The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease , 2006, Annals of Internal Medicine.

[33]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[34]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[35]  T. Saibara,et al.  Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. , 2004, Journal of hepatology.

[36]  P Christoffersen,et al.  Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.

[37]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[38]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[39]  Diagnosis and Classification of Diabetes Mellitus , 2003 .

[40]  Shohei Matsuzaki,et al.  Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background , 2003, Journal of Gastroenterology.

[41]  H. Senturk,et al.  Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis , 2002, American Journal of Gastroenterology.

[42]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[43]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[44]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[45]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[46]  C. Day,et al.  Non-alcoholic steatohepatitis: another disease of affluence , 1999, The Lancet.

[47]  M. Bennett,et al.  The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.